Circulating inflammation markers and prostate cancer.

Chronic inflammation is thought to influence the risk of prostate cancer. The purpose of this population-based case-control study was to evaluate the association of 48 circulating inflammation markers with prostate cancer, to identify candidate markers for further investigation.

Serum samples collected from 235 prostate cancer patients and 198 population-based controls recruited in Örebro County, Sweden, in 1989-1991, were assessed using a multiplex bead-based immunoassay to determine concentrations of 48 circulating inflammation markers. Logistic regression was first used to evaluate the association between individual markers (highest vs lowest concentration quartile) and prostate cancer in unadjusted and mutually adjusted models. Second, patients with inflammatory conditions, metastatic or advanced prostate cancer, were excluded to address the possible influence of systemic disease on inflammation markers.

Individual analyses first identified 21 markers associated with prostate cancer (P < .05), which after mutual adjustment were reduced to seven markers. After the exclusion of men with conditions linked with systemic inflammation, associations between prostate cancer and deviant levels of C-X3-C motif chemokine ligand 1, platelet-derived growth factor subunit B homodimer, interleukin 10, C-C motif chemokine ligand (CCL) 21, and CCL11 remained statistically significant.

In this explorative study, we identified candidate inflammation markers of possible importance for prostate cancer pathophysiology, for further evaluation in prospective studies.

The Prostate. 2019 Jun 18 [Epub ahead of print]

Henrik Ugge, Mary K Downer, Jessica Carlsson, Michaela Bowden, Sabina Davidsson, Lorelei A Mucci, Katja Fall, Sven-Olof Andersson, Ove Andrén

Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts., Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Department of Clinical epidemiology and biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe